Search: onr:"swepub:oai:lup.lub.lu.se:5726a920-31ef-404a-b2a3-3a6e4ecca81b" >
Pulse Versus Daily ...
Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
-
de Groot, Kirsten (author)
-
Harper, Lorraine (author)
-
Jayne, David R. W. (author)
-
show more...
-
Suarez, Luis Felipe Flores (author)
-
Gregorini, Gina (author)
-
Gross, Wolfgang L. (author)
-
Luqmani, Rashid (author)
-
Pusey, Charles D. (author)
-
Rasmussen, Niels (author)
-
Sinico, Renato A. (author)
-
Tesar, Vladimir (author)
-
Vanhille, Philippe (author)
-
- Westman, Kerstin (author)
- Lund University,Lunds universitet,Njurmedicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Nephrology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Savage, Caroline O. S. (author)
-
show less...
-
(creator_code:org_t)
- 2009
- 2009
- English.
-
In: Annals of Internal Medicine. - 0003-4819. ; 150:10, s. 3-670
- Related links:
-
http://www.annals.or... (free)
-
show more...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- Background: Current therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are limited by toxicity. Objective: To compare pulse cyclophosphamide with daily oral cyclophosphamide for induction of remission. Design: Randomized, controlled trial. Random assignments were computer-generated; allocation was concealed by faxing centralized treatment assignment to providers at the time of enrollment. Patients, investigators, and assessors of outcomes were not blinded to assignment. Setting: 42 centers in 12 European countries. Patients: 149 patients who had newly diagnosed generalized ANCA-associated vasculitis with renal involvement but not immediately life-threatening disease. Intervention: Pulse cyclophosphamide, 15 mg/kg every 2 to 3 weeks (76 patients), or daily oral cyclophosphamide, 2 mg/kg per day (73 patients), plus prednisolone. Measurement: Time to remission (primary outcome); change in renal function, adverse events, and cumulative dose of cyclophosphamide (secondary outcomes). Results: Groups did not differ in time to remission (hazard ratio, 1.098 [95% CI, 0.78 to 1.55]; P = 0.59) or proportion of patients who achieved remission at 9 months (88.1% vs. 87.7%). Thirteen patients in the pulse group and 6 in the daily oral group achieved remission by 9 months and subsequently had relapse. Absolute cumulative cyclophosphamide dose in the daily oral group was greater than that in the pulse group (15.9 g [interquartile range, 11 to 22.5 g] vs. 8.2 g [interquartile range, 5.95 to 10.55 g]; P < 0.001). The pulse group had a lower rate of leukopenia (hazard ratio, 0.41 [CI, 0.23 to 0.71]). Limitations: The study was not powered to detect a difference in relapse rates between the 2 groups. Duration of follow-up was limited. Conclusion: The pulse cyclophosphamide regimen induced remission of ANCA-associated vasculitis as well as the daily oral regimen at a reduced cumulative cyclophosphamide dose and caused fewer cases of leukopenia. Primary Funding Source: The European Union.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
de Groot, Kirste ...
-
Harper, Lorraine
-
Jayne, David R. ...
-
Suarez, Luis Fel ...
-
Gregorini, Gina
-
Gross, Wolfgang ...
-
show more...
-
Luqmani, Rashid
-
Pusey, Charles D ...
-
Rasmussen, Niels
-
Sinico, Renato A ...
-
Tesar, Vladimir
-
Vanhille, Philip ...
-
Westman, Kerstin
-
Savage, Caroline ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Urology and Neph ...
- Articles in the publication
-
Annals of Intern ...
- By the university
-
Lund University